What were the key drivers of Corteva's revenue growth in the first quarter of 2023?

Corteva's revenue growth was primarily driven by a 14% increase in price, reflecting its 'price for value' strategy and efforts to recover higher input costs. This was partially offset by a 4% decrease in volume and a 5% unfavorable currency impact.

How did the recent acquisitions of Stoller and Symborg impact the financial results?

The acquisitions of Stoller and Symborg, completed on March 1, 2023, were significant strategic moves to bolster Corteva's biologicals and microbiological technologies. While their operating results did not materially impact the Q1 2023 financial statements due to their recent completion, they were factored into the raised full-year 2023 financial guidance, contributing to the increased sales and Operating EBITDA expectations.

What is Corteva's outlook for the full year 2023?

Corteva has updated its full-year 2023 guidance, now expecting net sales between $18.6 billion and $18.9 billion, and Operating EBITDA between $3.55 billion and $3.75 billion. Operating Earnings Per Share is projected to be between $2.80 and $3.00. This updated outlook incorporates the contributions from the recent acquisitions.

How is Corteva returning capital to shareholders?

In the first quarter of 2023, Corteva returned approximately $360 million to shareholders through common stock dividends and share repurchases. The company completed its 2021 $1.5 billion share repurchase program during this quarter and continues to execute its $2 billion share repurchase program authorized in September 2022.

CTVA 10-Q Quarterly Report Q1 FY2023 — Revenue, Net Income, EPS

Summary

Corteva, Inc. reported a net sales increase of 6% to $4.88 billion for the first quarter of 2023, driven by a 14% price increase, partially offset by a 4% volume decrease and a 5% unfavorable currency impact. Net income increased to $595 million, or $0.83 per diluted share, compared to $564 million, or $0.78 per diluted share, in the prior year's quarter. The company completed significant acquisitions of Stoller Group, Inc. and Quorum Vital Investment, S.L. (Symborg) for a combined $1.6 billion, strengthening its biologicals and microbiological technologies portfolio. Corteva also updated its full-year 2023 guidance, raising its net sales and Operating EBITDA expectations to reflect the impact of these acquisitions.

Financial Highlights

53 data points

Beta

Revenue

$4.88B

0.4% Gross Margin

Net Income

$595.00M

0.1% Net Margin

EPS (Diluted)

$0.83

Total Assets

$45.50B

Cash & Equivalents

$1.65B

Free Cash Flow

-$3.31B

Financial Statements

Beta

Revenue	$4.88B
Cost of Revenue	$2.77B
Gross Profit	$2.11B
R&D Expenses	$316.00M
SG&A Expenses	$726.00M
Net Income	$595.00M
EPS (Basic)	$0.84
EPS (Diluted)	$0.83
Shares Outstanding (Basic)	712.90M
Shares Outstanding (Diluted)	716.20M

Key Highlights

1Net sales increased 6% to $4.88 billion in Q1 2023 compared to Q1 2022.
2Diluted Earnings Per Share (EPS) rose to $0.83 from $0.78 year-over-year.
3Acquisition of Stoller Group and Symborg completed for $1.6 billion to enhance biologicals and microbiological offerings.
4Operating EBITDA improved by 18.5% to $1.23 billion compared to the prior year.
5The company raised its full-year 2023 sales and Operating EBITDA guidance.
6Shareholder returns through dividends and share repurchases totaled $360 million in Q1 2023.

Corteva, Inc. Quarterly Report for Q1 Ended Mar 31, 2023

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions